EN DE
Watch Sanara Medtech Inc for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Sanara Medtech Inc (SMTI) fair value: what the stock is really worth

As of Nov 9, 2026: fair value (intrinsic value) of Sanara Medtech Inc stock $14.55, price $32.10, that is 54.7% below the price, quality 50 out of 100. Rating: strongly overvalued. Calculated from audited financials with 12 of our 26 valuation models and 37 quality factors, updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

SM Sanara Medtech Inc logo Some data Nov 8, 2026

Sanara Medtech Inc

SMTI · US
Solid, but very expensive

Our calculation puts a fair price 55% below what the stock costs today.

Generates free cash flow
Quality 50/100
Mixed Growth (revenue 5y +45.9 %/yr in USD)
Some data
Fair value $14.55 · Strongly overvalued
Loss-making · -29.2% net margin (TTM)
High debt
Trails peers (1/11)
Narrow moat 18/100 · thin data
Watch Sanara Medtech Inc for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$49.68 $16.34 Fair Value $14.55 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 8, 2026.

How to read this chart

60‑month range $16.34 – $49.68 · fair‑value band $7.45 – $25.64 · the $32.10 price screens above the $14.55 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 8, 2026.

Follow Sanara Medtech in your weekly email

Every Wednesday you see whether Sanara Medtech is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States.

Show moreShow less

The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns.

It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement.

The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body.

Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.

Stock analysis

Sanara Medtech Inc (SMTI) currently trades at $32.10, while our model-based Fair Value estimate is $14.55, 55% below the price, so the stock looks overvalued today.

Show more

Valuation

Bull case: the DCF Models group reads highest at a median of $18.61 per share, and 3 of the 12 models we run sit above the $32.10 price.

Bear case: the Earnings-Based group reads lowest at $4.42, and 9 of the 12 models stay below the price. Data coverage for this calculation is medium.

Scenario range: $7.45 (bear) to $25.64 (bull), the price of $32.10 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 50/100 (solid quality), in the Healthcare sector.

Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.

Sanara Medtech Inc reported revenue of $103M in FY2025 versus $24.1M in FY2021, a compound +43.8%/yr. Reported net income was −$37.6M in FY2025.

Key figures

Market cap $295M Micro · P/S ratio 2.75 · EPS (TTM) $−0.0400 · Net margin −36.4% · Return on equity −1.3% · Return on assets (EBIT) −8.3% (5-year average) · Operating margin 6.3% · Revenue (TTM) $110M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (low confidence).

What moves the price

The share trades about 9% below its 52-week high and 96% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −44% fair-value upside, at −55%, SMTI screens richer than that median.

Fair Value models

Bear $7.45 Fair Value $14.55 Bull $25.64
Price $32.10 · Downside -54.7%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
EPV $3.56 $4.42 $5.13 74
FCF DCF $8.17 $13.05 $27.42 73
Growth DCF $7.45 $14.55 $25.64 73
All 12 models by family
DCF Models
FCF DCF $8.17 $13.05 $27.42 73
5Y Revenue Exit $7.13 $14.40 $29.60 65
5Y EBITDA Exit $29.42 $59.41 $118.36 68
10Y Revenue Exit $7.19 $18.61 $25.63 63
10Y EBITDA Exit $21.89 $60.92 $131.56 60
Earnings-Based
EPV $3.56 $4.42 $5.13 74
Multiples
EV/EBIT $9.25 $13.48 $17.71 65
EV/EBITDA $39.65 $54.01 $68.37 67
EV/Revenue $5.62 $9.50 $13.38 52
Growth DCF
Growth DCF $7.45 $14.55 $25.64 73
Rev-Margin DCF $8.19 $16.93 $35.22 65
Economic Profit
ROIC Compounder $5.35 $9.34 $11.56 69

Open the full fair value analysis →

Quality Score breakdown

Overall quality 50/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 40
How much profit the company makes from its sales and capital
Quality Growth 65
Are margins and returns getting better?
Cashflow 19
Do the profits arrive as real cash?
Financial strength 39
Debt, balance sheet and risk of trouble
Investment 85
Does it invest with discipline instead of growing at any price?
Low Volatility 26
How calm the share price moves, does not count
Price momentum 67
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 67
Distance to the 52-week high, does not count
New shares 72
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

Plus 10 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 9, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 54/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+19.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+31.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+45.9%
Start year 2020 (pandemic). Over 10 years: +40.8% a year
Revenue growth 26 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+15.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−32.3% (2020) → 8.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Growth Forecast

A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+55.5%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +51.9% a year for the price.

SMTI screens overvalued: fair value 55% below the price. Compare with Intuitive Surgical, Inc →

Compare Sanara Medtech Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 181 stocks

Beats the industry median on 1/10 measures
Overall it trails its industry peers.
Valuation
Quality Score 50 · Below median
Fair Value upside −54.7% · Bottom 25%
Profitability
Return on assets −51.5% · Bottom 25%
Net margin (12 months) −29.2% · Bottom 25%
Operating margin (12 months) 6.3% · Below median
Growth and dividend
Revenue growth (quarter YoY) 9.0% · Above median
Balance sheet
Debt / equity 7.75× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

P/B 49.68× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 2.68× · Pricier than median
Price / free cash flow (fiscal year) 136.3× · Priciest 25%
EV/EBITDA 25.4× · Priciest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 25
FUTURE (revenue growth)45 · sector 40
PAST (return on equity)0 · sector 30
HEALTH (low debt)0 · sector 96
DIVIDEND (yield)0 · sector 32

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Solventum Corporation SOLV $90.43 $131.27 +45% vs SMTI
EssilorLuxottica Société anonyme EL €190.60 €196.22 +3% vs SMTI
Intuitive Surgical, Inc ISRG $460.56 $353.90 −23% vs SMTI
Medline Inc MDLN $40.71 $28.59 −30% vs SMTI
Alcon Inc ALC CHF 61.22 CHF 34.06 −44% vs SMTI
Becton, Dickinson and Company BDX $215.25 $97.80 −55% vs SMTI
Straumann Holding STMN CHF 105.45 CHF 45.50 −57% vs SMTI
West Pharmaceutical Services, Inc WST $413.09 $139.22 −66% vs SMTI
Sartorius Stedim Biotech S.A DIM €226.20 €54.82 −76% vs SMTI
Sartorius Aktiengesellschaft SRT €229.00 €42.50 −81% vs SMTI

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Sanara Medtech Inc: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Sanara Medtech Inc Fair Value". https://www.fairvalue-calculator.com/stock/SMTI

Frequently asked questions

Is Sanara Medtech Inc (SMTI) overvalued or undervalued?
As of Nov 8, 2026, our model estimates a fair value of $14.55 versus a price of $32.10, about 55% lower (overvalued).
What is the fair value of SMTI?
Our model-based fair value for Sanara Medtech Inc is $14.55 (as of Nov 8, 2026), built from audited fundamentals. The current price: $32.10.
What is the quality score of SMTI?
Sanara Medtech Inc has a Quality Score of 50/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sanara Medtech Inc (SMTI)?
Our model-based price target is the fair value of $14.55 (as of Nov 8, 2026) from 12 valuation models. Cautious scenario $7.45, optimistic scenario $25.64. It is a calculation from audited fundamentals, not an analyst target.
What is the Sanara Medtech Inc stock forecast for 2026?
Our models put fair value at $14.55, about 55% lower versus a price of $32.10 (overvalued). Cautious scenario $7.45, optimistic scenario $25.64. The calculation is refreshed regularly with new filings.
What is the revenue of Sanara Medtech Inc (SMTI)?
Sanara Medtech Inc reported trailing-twelve-month revenue of about $110M (latest available figure, as of Nov 8, 2026).
What growth is priced into Sanara Medtech Inc (SMTI)?
For today's price to be fair in a discounted-cash-flow model, Sanara Medtech Inc would have to grow free cash flow by +55.5 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +45.9 % per year. As of Nov 8, 2026.
What discount rate (WACC) does the fair value of SMTI use?
Our models discount Sanara Medtech Inc at 11.8 %: a base by market capitalisation (small), damped by beta 1.19, country premium for USA. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sanara Medtech Inc that is +55.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has Sanara Medtech Inc (SMTI) delivered so far?
Over the past 5 years revenue at Sanara Medtech Inc grew +45.9 % a year. The price currently implies free-cash-flow growth of +55.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sanara Medtech Inc (SMTI) growing?
The median revenue growth in the sector is +6.3 % a year. That is the yardstick for the growth priced into Sanara Medtech Inc (+55.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sanara Medtech Inc (SMTI)?
The free-cash-flow yield on the price is 0.78 %: that much free cash flow Sanara Medtech Inc produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sanara Medtech Inc (SMTI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sanara Medtech Inc it is $14.55 per share (as of Nov 8, 2026), against a price of $32.10. It is the blended result of 12 valuation models in 5 families (DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit).
Is Sanara Medtech Inc stock overvalued or undervalued in 2026?
As of Nov 8, 2026, SMTI trades above its calculated fair value: price $32.10, fair value $14.55, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of SMTI?
No. The price is what the market pays today ($32.10); the fair value is what the company's own numbers justify ($14.55). For Sanara Medtech Inc the two are $17.55 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sanara Medtech Inc worth?
The market values Sanara Medtech Inc at about $295M (market capitalisation, as of Nov 8, 2026). Per share that is $32.10; our models calculate a fair value of $14.55 per share.
What do the bullish and bearish scenarios say about SMTI?
Our models span a range for Sanara Medtech Inc: cautious scenario $7.45, base $14.55, optimistic $25.64 per share (as of Nov 8, 2026, price $32.10). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sanara Medtech Inc (SMTI)?
Balance-sheet figures for Sanara Medtech Inc (as of Nov 8, 2026): return on equity −1.3%, debt of 7.75 per unit of equity. They feed the Quality Score of 50/100, which measures business quality independently of the share price.
How far is SMTI from its 52-week high?
Sanara Medtech Inc trades at $32.10, about 9% below its 52-week high of $35.28 and 96% above the low of $16.34 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of $14.55 is for.
Which stocks are comparable to Sanara Medtech Inc?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Becton, Dickinson and Company, Medline Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sanara Medtech Inc stock attractive at the current price?
The data as of Nov 8, 2026: price $32.10, calculated fair value $14.55 (−55%), Quality Score 50/100, from 12 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of SMTI calculated?
We run Sanara Medtech Inc through 12 models from 5 families: DCF Models, Earnings-Based, Multiples, Growth DCF, Economic Profit. Every model gets the same audited fundamentals; the fair value of $14.55 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.7% above its aggregate fair value. Sanara Medtech Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sanara Medtech Inc (SMTI)?
The closing price on Nov 9, 2026 was $32.10. Our model-based fair value is $14.55, about 55% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sanara Medtech Inc right now?
The price sits above even our optimistic bull case ($25.64). The favourable scenario is already priced in. The model range is unusually wide ($7.45 to $25.64). The outcome hinges heavily on assumptions, so read the point estimate with caution. Solid but not exceptional quality (50/100) and above fair value, neither a clear bargain nor a standout compounder.

Key figures of Sanara Medtech Inc

How large is the market capitalisation of Sanara Medtech Inc (SMTI)?
The market capitalisation of Sanara Medtech Inc is $295M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sanara Medtech Inc (SMTI)?
The price-to-sales ratio of Sanara Medtech Inc is 2.75 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sanara Medtech Inc (SMTI)?
Earnings per share at Sanara Medtech Inc are $−0.0400. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of Sanara Medtech Inc (SMTI)?
The net margin of Sanara Medtech Inc is −36.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sanara Medtech Inc (SMTI)?
The return on equity (ROE) of Sanara Medtech Inc is −1.3% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sanara Medtech Inc (SMTI)?
On an EBIT basis the return on assets of Sanara Medtech Inc is −8.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sanara Medtech Inc (SMTI)?
The operating margin of Sanara Medtech Inc is 6.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sanara Medtech Inc (SMTI)?
Revenue at Sanara Medtech Inc is growing +9.0% versus a year earlier (3y avg +31.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does Sanara Medtech Inc (SMTI) carry?
The net debt of Sanara Medtech Inc is $31.6M (fiscal year 2025, ≈ 14.6 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch Sanara Medtech Inc in the live analysis

One click puts Sanara Medtech Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.